DocMorris AG

ROSE

CH0042615283

Drug Retailers

Real-time Estimate Cboe Europe Other stock markets 09:44:41 2024-04-16 am EDT			5-day change	1st Jan Change
90.88 ^CHF	+3.33%		-1.08%	+24.61%

10:41am	DOCMORRIS : Warburg Research reiterates its Buy rating	ZD
09:05am	DOCMORRIS : UBS reaffirms its Sell rating	ZD

ZUR ROSE GROUP : Jefferies keeps its Buy rating

August 19, 2022 at 01:16 pm EDT

Jefferies is positive on the stock with a Buy rating. The target price is revised downwards from CHF 290 to CHF 95.

Latest news about DocMorris AG

DOCMORRIS : Warburg Research reiterates its Buy rating	04:41am	ZD
DOCMORRIS : UBS reaffirms its Sell rating	03:05am	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	02:40am	ZD
Swiss online drug delivery firm DocMorris reports slight miss in Q1 sales	01:21am	RE
DOCMORRIS : Jefferies keeps its Buy rating	Apr. 12	ZD
DOCMORRIS : Hauck & Aufhauser raises its recommendation to Buy	Apr. 12	ZD
DOCMORRIS : Deutsche Bank reaffirms its Buy rating	Apr. 11	ZD
DOCMORRIS : Receives a Buy rating from Jefferies	Apr. 10	ZD
DOCMORRIS : Baader Bank reaffirms its Buy rating	Apr. 10	ZD
DOCMORRIS : Warburg Research keeps its Buy rating	Apr. 10	ZD
DOCMORRIS : UBS reaffirms its Sell rating	Apr. 02	ZD
DOCMORRIS : Baader Bank maintains a Buy rating	Mar. 26	ZD
DOCMORRIS : Deutsche Bank keeps its Buy rating	Mar. 22	ZD
DOCMORRIS : Buy rating from Warburg Research	Mar. 22	ZD
DOCMORRIS : Receives a Buy rating from Warburg Research	Mar. 21	ZD
DOCMORRIS : Baader Bank remains its Buy rating	Mar. 21	ZD
Transcript : DocMorris AG, 2023 Earnings Call, Mar 21, 2024	Mar. 21
DOCMORRIS : Receives a Sell rating from UBS	Mar. 21	ZD
Business as usual	Mar. 21
DOCMORRIS : Jefferies remains its Buy rating	Mar. 21	ZD
DocMorris AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
DOCMORRIS : Jefferies remains its Buy rating	Mar. 14	ZD
DOCMORRIS : UBS reaffirms its Sell rating	Feb. 13	ZD
DOCMORRIS : Jefferies remains its Buy rating	Jan. 31	ZD
DOCMORRIS : Gets a Buy rating from Deutsche Bank	Jan. 17	ZD

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

01:00am - Q1 2024 Sales and Revenue Release - Trading Update

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

87.95 CHF

Average target price

95.49 CHF

Spread / Average Target

+8.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	+24.61%	1.13B
WALGREENS BOOTS ALLIANCE, INC.	-32.40%	15.23B
JD HEALTH INTERNATIONAL INC.	-40.54%	9.9B
MATSUKIYOCOCOKARA & CO.	-4.53%	6.83B
YIFENG PHARMACY CHAIN CO., LTD.	+9.14%	6.1B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-38.21%	5.59B
NAHDI MEDICAL COMPANY	+5.40%	5B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+49.08%	4.21B
CLICKS GROUP LIMITED	-11.42%	3.65B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-11.73%	3.46B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

ZUR ROSE GROUP : Jefferies keeps its Buy rating

Latest news about DocMorris AG

Chart DocMorris AG

Company Profile

Income Statement Evolution

Ratings for DocMorris AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers